---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-287698"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-11-17T23:59:59+00:00"
generated_at: "2026-06-21T16:44:48.921959+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Q3 net loss $4.49M; FDA clinical hold on IkT-148009 programs

## Summary
- Q3 2022 net loss of $4.49M ($0.18 per share) vs. $4.47M in Q3 2021.
- Cash, cash equivalents and marketable securities of $26.5M as of Sep 30, 2022.
- R&D expenses were $2.98M for Q3 2022, down from $3.15M in Q3 2021.
- FDA placed clinical hold on IkT-148009 for Parkinson's and MSA; 11 patients dosed with no serious adverse events.
- Appointed Gisele Dion to Board of Directors as Audit Committee chair.

## SEC filing metadata
- accession: 0001193125-22-287698
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-11-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/0001193125-22-287698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/d409524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-287698
- JSON: https://secwatch.observer/filing/0001193125-22-287698.json
- Plain text: https://secwatch.observer/filing/0001193125-22-287698.txt

## Key facts
- Earnings Releases
  Inhibikase Therapeutics, Inc. reported three months ended September 30, 2022 results: net income $4.49 million, EPS $0.18 per share.
  - Period: three months ended September 30, 2022
  - Net income: $4.49 million
  - EPS: $0.18 per share
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2022 was $4.49 million, or $0.18 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/0001193125-22-287698-index.htm
- Earnings Releases
  Inhibikase Therapeutics, Inc. reported nine months ended September 30, 2022 results: net income $13.78 million, EPS $0.55 per share.
  - Period: nine months ended September 30, 2022
  - Net income: $13.78 million
  - EPS: $0.55 per share
  - Result: reported results
  source text: Net loss for the nine months ended September 30, 2022, was $13.78 million or $0.55 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/0001193125-22-287698-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.